Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10776714 | 0.82 | ALDH1A1 (0.45) | APPKMT2AALDH1A1 | |
| SCHEMBL31494830 | 0.81 | CES2 (0.47) | CES2CES1BCHEKMT2A | |
| SCHEMBL17040320 | 0.79 | CTSK (0.43) | CES2CES1AAK1LMNAKMT2A | |
| SCHEMBL14721160 | 0.78 | ESR1 (0.42) | APPAAK1LMNAKMT2AALDH1A1 | |
| SCHEMBL5215418 | 0.78 | ESR1 (0.42) | APPAAK1LMNAKMT2AALDH1A1 | |
| SCHEMBL23081408 | 0.77 | CES2 (0.38) | CES2CES1GPR119LMNAKMT2A | |
| SCHEMBL7746373 | 0.77 | GABRA1 (0.47) | APPAAK1TRPV1LMNAKMT2A | |
| SCHEMBL31016144 | 0.77 | CYP4F2 (0.47) | GPR119LMNAALDH1A1 | |
| SCHEMBL16782680 | 0.76 | MEN1 (0.46) | LMNAKMT2AALDH1A1 | |
| SCHEMBL29348334 | 0.76 | APP (0.36) | APPAAK1TRPV1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | APP 804/4885CES2 4762/4885CES1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.